California, US — Graph AI, a start-up focused on patient safety and pharmacovigilance, has raised $3 million in Seed funding, led by Bessemer Venture Partners. The investment will support the company’s plans to accelerate product innovation, expand its engineering team, and advance global adoption of its AI-native safety platform.

The company represents part of a new generation of AI-first challengers transforming the pharmaceutical and life sciences industries — particularly the $8 billion pharmacovigilance sector. Pharmacovigilance, a key regulatory requirement for drug safety, obliges pharmaceutical companies to continuously detect, monitor, and report adverse drug events (ADEs) throughout a product’s lifecycle.

Traditionally, this process has relied on outsourcing to service firms employing large teams to manually gather and analyse data from multiple sources. Graph AI’s approach keeps humans involved only where required by regulation, while automating most workflows with AI. The result, the company says, is a significant leap in accuracy, efficiency, and compliance — reducing the time and cost associated with medical safety reviews.

Founded in 2024, Graph AI is led by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO) — veterans from global firms such as Infosys, Google, and ServiceNow.

Within just over a year, Graph AI reports strong traction with enterprise clients and a growing pipeline covering more than 7,000 drugs. Customers have recorded efficiency gains of up to 70%, 90% faster regulatory reporting, and major cost reductions — all while maintaining audit readiness and full traceability.

In a joint statement, the founders said:

“The life sciences industry still struggles with outdated systems, data silos, and manual handoffs that slow decision-making and heighten compliance risks. Graph AI is tackling these challenges with a unified, AI-native platform that fuses context, compliance, and intelligence into one connected ecosystem. Our goal is to make patient safety smarter, faster, and more integrated — helping pharmaceutical enterprises achieve stronger regulatory confidence and greater operational efficiency.”

Nithin Kaimal, Partner at Bessemer Venture Partners India, added:

“We’re delighted to back Graph AI as it redefines labour-intensive pharmacovigilance through scalable, AI-native solutions. This marks a shift from labour arbitrage to intelligence arbitrage — enabling enterprises to partner with firms that deliver faster, smarter, and more adaptive outcomes. We look forward to supporting Graph as it scales globally.”